SAN FRANCISCO – Takeda Pharmaceutical Co. has threatened to end its collaboration with Orexigen Therapeutics Inc. after a safety study of the obesity drug Contrave was halted by researchers who criticized Orexigen for an early release of trial data.
“Takeda sent a dispute letter to Orexigen on May 12 whereby Takeda seeks termination of its collaboration agreement with Orexigen based on Orexigen’s material breach of the agreement,” spokeswoman Sandy Rodriguez said Tuesday in an email.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.